GOVX · NASDAQ
Average $74.80 (+32837.0% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Noble Capital Markets | Sep 15, 2026 | Maintains | Outperform |
| D. Boral Capital | Apr 16, 2026 | Maintains | Hold |
| D. Boral Capital | Feb 19, 2026 | Downgrade | Buy → Hold |
| D. Boral Capital | Jan 21, 2026 | Maintains | Buy |
| D. Boral Capital | Nov 19, 2025 | Maintains | Buy |
Updated Aug 11, 2026
Geovax Labs is facing constrained near-term visibility and elevated execution risk, leading to a lowering of our rating from Buy to Hold due to limited catalysts and tightening capital resources. While the company has made progress in advancing GEO-MVA and strengthening its intellectual property, the recent $1M registered direct offering highlights potential funding constraints and increases the likelihood of additional dilutive capital raises for the company to advance its pipeline.
Geovax Labs is a clinical-stage biotechnology company with a negative outlook, due to the company's high reliance on its GEO-MVA platform, which is in its early stages with no approved products. In addition, the recent reverse stock split and low cash balance increase the risk of future dilution for investors. The company reported a decline in revenue and a net loss in 2025, highlighting its financial challenges and the need for external funding. While there are potential catalysts in the form of clinical progress and new studies, they are unlikely to impact the company's valuation in the near term, leading to a negative outlook.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
